Guardant Health (NASDAQ:GH) Insider John Saia Sells 10,000 Shares

by · The Cerbat Gem

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) insider John Saia sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $125.08, for a total transaction of $1,250,800.00. Following the completion of the transaction, the insider directly owned 35,950 shares of the company’s stock, valued at approximately $4,496,626. The trade was a 21.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Price Performance

NASDAQ:GH opened at $133.22 on Friday. The firm has a 50-day moving average of $94.23 and a two-hundred day moving average of $99.73. The stock has a market cap of $17.66 billion, a P/E ratio of -39.30 and a beta of 1.48. Guardant Health, Inc. has a 1-year low of $38.03 and a 1-year high of $133.71.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Guggenheim cut Guardant Health from a “buy” rating to a “buy” rating in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Canaccord Genuity Group increased their price target on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Wells Fargo & Company increased their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Finally, BTIG Research set a $160.00 price target on shares of Guardant Health and gave the stock a “buy” rating in a research report on Wednesday. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $129.79.

Check Out Our Latest Analysis on Guardant Health

Hedge Funds Weigh In On Guardant Health

A number of large investors have recently bought and sold shares of GH. AQR Capital Management LLC lifted its holdings in Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after acquiring an additional 25,831 shares during the last quarter. Empowered Funds LLC bought a new stake in Guardant Health in the first quarter valued at $274,000. Sei Investments Co. lifted its stake in Guardant Health by 15.8% in the second quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock valued at $4,023,000 after buying an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Guardant Health by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock valued at $32,922,000 after buying an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Guardant Health by 56.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after buying an additional 40,209 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

(Get Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Featured Articles